Brussels, Belgium, September 10, 2018
Univercells SA, a technology company dedicated to delivering innovative and cost-effective biomanufacturing solutions, announces the appointment of Dr. Pierre Morgon as member of the Board of Directors.
Dr. Pierre Morgon, a seasoned executive in the biotechnology and pharma sector, brings 30 years’ experience to Univercells, with a strong focus on commercial development and market access strategy for biologicals and vaccines.
Pierre Morgon is CEO of MRGN Advisors, regional partner at Mérieux Développement and a mentor for start-up life sciences companies at the Mass Challenge incubator in Switzerland. He also serves the boards of several companies, including Eurocine Vaccines, Theradiag, Vaccitech, and Virometix as the Chairman.
This appointment follows the recent Series B capital increase of €16 million led by Global Health Investment Fund (GHIF) and the appointment of Mr. Glenn Rockman as member of the Board of Directors. The capital increase will support Univercells’ breakthrough biologics manufacturing solutions with the potential to dramatically reduce the capital expenditure, physical footprint and operating costs required to produce biologics.
“All the stakeholders of the healthcare value chain agree that vaccines and biologics availability and affordably are an issue. From the influencers to the payers to the end users, the minds are prepared to seize the benefits offered by the Univercells’ technology. In addition to a foundation of remarkable technological science, the company founders are nurturing a healthy and dynamic work atmosphere. It has been a pleasure to support the company’s effort in more than one count and going forward, to maintain the Univercells momentum towards a broader portfolio and the promise for multiple digit expansion of revenue while creating a significant impact on global health.”, states Dr. Pierre Morgon.